bioAffinity closes $1.45M capital raise and reclassifies warrants adding $2.8M to equity

bioAffinity Technologies, Inc.

Private placement of 990 Series B Preferred shares convertible into ~4.3M common at $0.23/sh and warrants for ~6.7M shares at $0.352/sh, gross proceeds ~$1.2M.
Warrant inducement: existing warrants exercised at reduced $0.23/sh for $253K cash; new warrants for 1.43M shares at $0.352/sh pending stockholder approval.
Warrant amendment reclassifies May 2025 warrants from liability to equity, increasing stockholders' equity by ~$2.8M.
Anti-dilution adjustment on May 2025 warrants reduces exercise price to $0.23/sh and increases shares issuable by ~8M.
Authorized common shares increased from 100M to 350M.

item 1.01 item 3.02 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

bioAffinity Technologies, Inc.: Increased authorized shares of Common Stock from 100,000,000 to 350,000,000 and designated Series B Convertible Preferred Stock (effective 2025-08-13).

Change: charter amendment
Effective: 2025-08-13

Exact text from the filing

On August 13, 2025, the Company filed a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Certificate of Amendment”) to increase the number of authorized shares of the Company’s Common Stock from 100,000,000 to 350,000,000.

View on SEC.gov

Browse all governance changes →

bioAffinity Technologies, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-024172

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.